Provided by Tiger Trade Technology Pte. Ltd.

Silence Therapeutics Plc

13.28
-0.1400-1.04%
Volume:124.22K
Turnover:1.65M
Market Cap:799.58M
PE:-10.46
High:13.65
Open:13.39
Low:13.09
Close:13.42
52wk High:17.58
52wk Low:4.19
Shares:60.21M
Float Shares:48.23M
Volume Ratio:0.50
T/O Rate:0.26%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.2693
EPS(LYR):-1.8761
ROE:-90.41%
ROA:-29.65%
PB:20.78
PE(LYR):-7.08

Loading ...

European Equities Traded in the US as American Depositary Receipts Edge Lower in Monday Trading

MT Newswires Live
·
Yesterday

European Equities Traded in the US as American Depositary Receipts Head Lower in Tuesday Trading

MT Newswires Live
·
Aug 18

Analysts Offer Insights on Healthcare Companies: Silence Therapeutics (SLN), Cardinal Health (CAH) and Allogene Therapeutics (ALLO)

TIPRANKS
·
Aug 17

Silence Therapeutics Closes Upsized $201.3 Million ADS Follow-on Offering at $13.5 Each

Reuters
·
Aug 15

European Equities Traded in the US Rise in Thursday Trading

MT Newswires Live
·
Aug 13

Silence Therapeutics 10% Owner Richard Ian Griffiths Disposes of ADS Worth $87.88 Million

Reuters
·
Aug 13

U.S. Stocks on the MOVE-Sutro Biopharma, Humacyte

Reuters
·
Aug 13

Silence Therapeutics Prices Upsized $175 Million ADS Offering at $13.5 Each

Reuters
·
Aug 12

European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading

MT Newswires Live
·
Aug 11

Silence Therapeutics' Divesiran Data Support Best-in-Class Potential, Morgan Stanley Says

MT Newswires Live
·
Aug 11

Silence Therapeutics (SLN) Receives a Buy from Morgan Stanley

TIPRANKS
·
Aug 11

Silence Therapeutics Launches $150 Million ADS Follow-on Offering

Reuters
·
Aug 11

Top Midday Gainers

MT Newswires Live
·
Aug 11

Analysts Offer Insights on Healthcare Companies: Jade Biosciences (JBIO), Silence Therapeutics (SLN) and Vertex Pharmaceuticals (VRTX)

TIPRANKS
·
Aug 11

European Equities Traded in the US as American Depositary Receipts Edge Higher in Monday Trading

MT Newswires Live
·
Aug 10

Silence Therapeutics Shares up 32% After Q2 Results

THOMSON REUTERS
·
Aug 10

Silence Therapeutics Shares Climb on Blood-Cancer Trial Results

Dow Jones
·
Aug 10

Silence announces results from Phase 2 SANRECO trial met primary endpoint

TIPRANKS
·
Aug 10

Silence Therapeutics Says Phase 2 Sanreco Trial Meets Primary Endpoint for Divesiran in Polycythemia Vera

Reuters
·
Aug 10

Silence Therapeutics Q2 FY26 Net Loss Narrows to $12.3 Million; Revenue Falls to $0 from $224,000

Reuters
·
Aug 10